Stay updated on Risankizumab Maintenance in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab Maintenance in Psoriasis Clinical Trial page.

Latest updates to the Risankizumab Maintenance in Psoriasis Clinical Trial page
- Check6 days agoChange DetectedA line noting an NIH grant/contract funding source was added to the study details, clarifying the source of support for this risankizumab maintenance trial.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision label was updated from v3.6.4 to v3.6.5, indicating a small internal update to the page. It does not modify the study details, eligibility criteria, or results information, and seems to be an internal versioning change.SummaryDifference0.0%

- Check41 days agoChange DetectedFooter now shows Revision: v3.6.4, replacing the previous Revision: v3.6.3. This reflects a minor version update of the page's documentation and does not alter study details or content.SummaryDifference0.0%

- Check62 days agoChange DetectedThe page's revision label in the footer was updated from v3.6.0 to v3.6.3, indicating a newer build/version of the page.SummaryDifference0.0%

- Check77 days agoChange DetectedRecruitment status was updated with a new note that the study is no longer looking for participants. Additional navigation and labeling updates were added, including How to Read a Study Record, Common Questions, How to Join a Study, and Intervention/Treatment, along with the Revision: v3.6.0 label.SummaryDifference0.1%

- Check83 days agoChange DetectedRevision: v3.5.5 has been applied, replacing the previous Revision: v3.5.4. This represents a minor software update to the interface and does not modify any study data or displayed content.SummaryDifference0.0%

Stay in the know with updates to Risankizumab Maintenance in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab Maintenance in Psoriasis Clinical Trial page.